Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows
VYGR•Outlook
Voyager expects to begin dosing VY1706 in early Alzheimer's patients in the fourth quarter of 2026. The company also anticipates tau PET imaging data for VY7523 in the fourth quarter of 2026.
Analyst coverage
The current average analyst rating on the shares is strong buy, with 11 "strong buy" or "buy" recommendations, no "hold" ratings, and no "sell" or "strong sell" ratings.
The average consensus recommendation for the biotechnology & medical research peer group is buy. Wall Street's median 12-month price target for Voyager Therapeutics, Inc. is $12.00, about 287.1% above its August 5 closing price of $3.10.
Quarterly results
Voyager Therapeutics said second-quarter collaboration revenue fell year over year as Neurocrine activities moved past the research phase. The company also said its second-quarter net loss narrowed from the prior year as research and development and general and administrative expenses declined.
| Metric | Actual |
|---|---|
| Q2 Collaboration Revenue | $3.17 mln |
| Q2 Net Loss | $24.47 mln |
| Q2 Loss Per Basic Share | $0.40 |
| Q2 Operating Income | -$26.39 mln |
| Q2 Pretax Loss | $24.45 mln |
Expense drivers and cash position
The company said lower second-quarter collaboration revenue was due to reduced revenue from the Neurocrine agreement as activities transition beyond the research phase.
